secwatch.observer — SEC 8-K summary
======================================

Issuer:     Estrella Immunopharma, Inc. (ESLA)
CIK:        0001844417
Form:       8-K
Filed at:   2023-10-05T23:59:59+00:00
Accession:  0001013762-23-002216
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 2.01, 1.01, 2.03, 3.02, 9.01, 3.01, 3.03, 5.03, 5.01, 5.02, 5.05, 5.06
LLM model:  deepseek-v4-flash:cloud@v2

TradeUP Acquisition Corp completes merger with Estrella Biopharma; becomes Estrella Immunopharma, listing on Nasdaq
--------------------------------------------------------------------------------

- Merger consideration of $325M; Estrella stockholders receive 32.5M shares; name changes to Estrella Immunopharma.
- Gross proceeds of ~$23.11M from PIPE ($10M) and Series A sales ($9.75M); funds expected to support operations into 2024.
- Officers/directors own ~92.3% of outstanding shares; former UPTD holders own ~4.8%.
- Common stock (ESLA) and warrants (ESLAW) start trading on Nasdaq on Oct 2, 2023.
- Entered into $50M equity line with White Lion Capital; 3.5M shares authorized under 2023 Incentive Plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1844417/000101376223002216/0001013762-23-002216-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1844417/000101376223002216/ea185637-8k_estrella.htm
  HTML page:      https://secwatch.observer/filing/0001013762-23-002216

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer